Teknova Announces Early Access Program for Novel Products to Address Critical Pain Points in Gene Therapy Bioproduction
13 October 2022 - 11:00PM
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider
of critical reagents for the discovery, development, and
commercialization of drug therapies, novel vaccines, and molecular
diagnostics, announced the creation of an Early Access Program for
two new products currently in development to streamline downstream
gene therapy process development, including an Anion Exchange (AEX)
Buffer Screening Kit and a Functional Reporter Assay. The company
also announced the upcoming launch of a new WFI Quality Water
product, to be made available through the company’s online catalog
offering in November.
Speaking at the Annual Cell & Gene Meeting on the Mesa,
Stephen Gunstream, Teknova’s President and Chief Executive Officer,
highlighted that the Company’s Research and Development team is
focused on the development of novel products and services to
address critical pain points in the development of gene
therapies.
“We are leveraging our expertise in end-to-end gene therapy
workflows to develop new custom product innovations aimed at
addressing key bioprocessing bottlenecks,” said Mr. Gunstream. “Our
initial products are aimed at streamlining the development of AAV
therapies by providing our customers the tools to quickly optimize
their process, enabling high recovery and purity of their AAV
product.”
The first product, an Anion Exchange (AEX) Buffer Screening Kit,
is designed to allow AAV gene therapy developers to rapidly
identify the optimal buffer formulation for capsid enrichment based
on their specific serotype, transgene, and AEX platform. The second
is a Functional Reporter Assay utilizing an RNA-sensing technology
intended to measure viral functional performance based on the gene
of interest.
Teknova is still in early-stage development of the AEX Buffer
Screening Kit and the Functional Reporter Assay. To expedite and
promote the development of both products, they are seeking to
partner with companies currently entering or working in the
downstream AAV purification process. To learn more about Teknova’s
Early Access Program, visit www.teknova.com.
The company also announced that in response to customer interest
it will begin to manufacture WFI Quality Water, which will be made
available through its online catalog of products in 20L and 200L
bags, beginning in November 2022. The company will provide more
details as the launch date approaches.
About TeknovaTeknova is expediting clinical
breakthroughs in life sciences by providing custom products and
reagents for drug therapies, novel vaccines, and molecular
diagnostics. With a focus on agility and customization, Teknova
delivers research-grade and GMP products, including cell culture
media and supplements, protein and nucleic acid purification
buffers, and molecular biology reagents for a multitude of
established and emerging applications, including cell and gene
therapy, mRNA therapeutics, genomics, and synthetic biology.
Teknova's proprietary processes enable the manufacture and delivery
of high-quality, custom, made-to-order products with short
turnaround times and at scale across all stages of development,
including commercialization.
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
Media Contact
Jenn Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Apr 2023 to Apr 2024